| Literature DB >> 16339704 |
Joanne M Donovan1, Melissa Plone, Rafif Dagher, Mark Bree, Judith Marquis.
Abstract
Deferitrin, a novel, orally available iron chelator, is in the early stage of clinical development for the treatment of chronic iron overload due to transfusional therapy. Preclinical pharmacology studies demonstrate iron excretion largely by the fecal route. Initial clinical studies have shown deferitrin to be well absorbed. Further clinical studies are ongoing to determine the efficiency and safety of deferitrin.Entities:
Mesh:
Substances:
Year: 2005 PMID: 16339704 DOI: 10.1196/annals.1345.071
Source DB: PubMed Journal: Ann N Y Acad Sci ISSN: 0077-8923 Impact factor: 5.691